Bayer Shares Fall After Clinical Trial Failure, Roundup Loss

Bayer shares fell sharply after the company prematurely stopped a late-stage study of a blood-thinning drug due to lack of effectiveness and was asked to pay $1.56 billion in a lawsuit over its Roundup weedkiller.

Bayer announced Sunday evening that it had halted a phase 3 clinical trial to test its experimental drug, asundexian, for the prevention of stroke and systemic embolism in patients with heart rhythm disorders, atrial fibrillation .